XML 12 R2.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated statements of profit or loss and other comprehensive income - AUD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Revenue and other income      
Revenue $ 42 $ 2,308 $ 0
Other income 1,787 173 1
Finance income 72 12 22
Expenses      
Research and development expense (7,326) (17,380) (15,564)
General and administrative expense (8,720) (13,563) (8,583)
Impairment of intangible assets (13,379) 0 0
(Loss) gain on remeasurement of other financial liabilities (2,478) 1,257 0
Gain on remeasurement of promissory note 0 25 0
Gain on remeasurement of contingent consideration 7,554 119 3,388
Loss before income tax benefit (22,448) (27,049) (20,736)
Income tax benefit 1,746 271 271
Loss after income tax benefit (20,702) (26,778) (20,465)
Items that may be reclassified subsequently to profit or loss      
Net exchange difference on translation of financial statements of foreign controlled entities, net of tax (23) (8) 110
Other comprehensive income (loss), net of tax (23) (8) 110
Total comprehensive income/(loss) $ (20,725) $ (26,786) $ (20,355)
Earnings per share for loss attributable to the owners of Kazia Therapeutics Limited      
Basic earnings per share $ (0.0378) $ (0.1016) $ (0.1123)
Diluted earnings per share $ (0.0378) $ (0.1016) $ (0.1123)